دورية أكاديمية
Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
| العنوان: | Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. |
|---|---|
| المؤلفون: | Brada LJH; Department of Surgery, UMC Utrecht Cancer Center, St Antonius Hospital Nieuwegein and Meander Medical Center, Utrecht, The Netherlands.; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Walma MS; Department of Surgery, UMC Utrecht Cancer Center, St Antonius Hospital Nieuwegein and Meander Medical Center, Utrecht, The Netherlands.; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Daamen LA; Department of Surgery, UMC Utrecht Cancer Center, St Antonius Hospital Nieuwegein and Meander Medical Center, Utrecht, The Netherlands., van Roessel S; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van Dam RM; Department of Surgery, Maastricht UMC+, Maastricht, The Netherlands., de Hingh IH; Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.; Department of Epidemiology, Maastricht University, Maastricht, The Netherlands., Liem MLS; Department of Surgery, Medical Spectrum Twente, Enschede, The Netherlands., de Meijer VE; Department of Surgery, UMC Groningen, Groningen, The Netherlands., Patijn GA; Department of Surgery, Isala, Zwolle, The Netherlands., Festen S; Department of Surgery, OLVG, Amsterdam, The Netherlands., Stommel MWJ; Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands., Bosscha K; Department of Surgery, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Polée MB; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Yung Nio C; Department of Radiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Wessels FJ; Department of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht University, Utrecht, The Netherlands., de Vries JJJ; Department of Radiology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands., van Lienden KP; Department of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht University, Utrecht, The Netherlands., Bruijnen RC; Department of Radiology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht University, Utrecht, The Netherlands., Los M; Department of Medical Oncology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, Utrecht, The Netherlands., Mohammad NH; Department of Medical Oncology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, Utrecht, The Netherlands., Wilmink HW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Busch OR; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Besselink MG; Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Quintus Molenaar I; Department of Surgery, UMC Utrecht Cancer Center, St Antonius Hospital Nieuwegein and Meander Medical Center, Utrecht, The Netherlands., van Santvoort HC; Department of Surgery, UMC Utrecht Cancer Center, St Antonius Hospital Nieuwegein and Meander Medical Center, Utrecht, The Netherlands. |
| مؤلفون مشاركون: | Dutch Pancreatic Cancer Group |
| المصدر: | Journal of surgical oncology [J Surg Oncol] 2021 Sep; Vol. 124 (4), pp. 589-597. Date of Electronic Publication: 2021 Jun 11. |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0222643 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9098 (Electronic) Linking ISSN: 00224790 NLM ISO Abbreviation: J Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005-> : Hoboken, NJ : Wiley-Liss Original Publication: New York, Plenum. |
| مواضيع طبية MeSH: | Nomograms*, Adenocarcinoma/*mortality , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Pancreatectomy/*mortality , Pancreatic Neoplasms/*mortality, Adenocarcinoma/pathology ; Adenocarcinoma/therapy ; Aged ; Combined Modality Therapy ; Female ; Fluorouracil/therapeutic use ; Follow-Up Studies ; Humans ; Irinotecan/therapeutic use ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Oxaliplatin/therapeutic use ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/therapy ; Prognosis ; Prospective Studies ; Survival Rate |
| مستخلص: | Background and Objectives: Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable. It remains unclear, however, which specific patients benefit from FOLFIRINOX. Two nomograms were developed predicting overall survival (OS) and resection at the start of FOLFIRINOX for LAPC. Methods: From our multicenter, prospective LAPC registry in 14 Dutch hospitals, LAPC patients starting first-line FOLFIRINOX (April 2015-December 2017) were included. Stepwise backward selection according to the Akaike Information Criterion was used to identify independent baseline predictors for OS and resection. Two prognostic nomograms were generated. Results: A total of 252 patients were included, with a median OS of 14 months. Thirty-two patients (13%) underwent resection, with a median OS of 23 months. Older age, female sex, Charlson Comorbidity Index ≤1, and CA 19.9 < 274 were independent factors predicting a better OS (c-index: 0.61). WHO ps >1, involvement of the superior mesenteric artery, celiac trunk, and superior mesenteric vein ≥ 270° were independent factors decreasing the probability of resection (c-index: 0.79). Conclusions: Two nomograms were developed to predict OS and resection in patients with LAPC before starting treatment with FOLFIRINOX. These nomograms could be beneficial in the shared decision-making process and counseling of these patients. (© 2021 Wiley Periodicals LLC.) |
| References: | Reames BN , Blair AB , Krell RW , et al. Management of locally advanced pancreatic cancer: results of an international survey of current practice. Ann Surg. 2019;273:1173-1181. Philip PA . Locally advanced pancreatic cancer: where should we go from here? J Clin Oncol. 2011;29(31):4066-4068. Tempero MA , Malafa MP , Al-Hawary M , et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028-1061. Abendroth A , Noureddine R , Abramczyk M , et al. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol. 2019;145(2):445-455. Suker M , Beumer BR , Sadot E , et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801-810. Rombouts SJ , Walma MS , Vogel JA , et al. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2016;23(13):4352-4360. Sadot E , Doussot A , O'reilly EM , et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512-3521. Maggino L , Malleo G , Marchegiani G , et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932-942. Conroy T , Desseigne F , Ychou M , et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. Rombouts SJ , Mungroop TH , Heilmann MN , et al. FOLFIRINOX in locally advanced and metastatic pancreatic cancer: a single centre cohort study. J Cancer. 2016;7(13):1861-1866. Hackert T , Sachsenmaier M , Hinz U , et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457-463. Gemenetzis G , Groot VP , Blair AB , et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340-347. Marthey L , Sa-Cunha A , Blanc JF , et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22(1):295-301. Balachandran VP , Gonen M , Smith JJ , DeMatteo RP . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173-e180. Strijker M , Mackay TM , Bonsing BA , et al. Establishing and Coordinating a Nationwide Multidisciplinary Study Group: lessons Learned by the Dutch Pancreatic Cancer Group. Ann Surg. 2020;271(4):e102-e104. Versteijne E , van Eijck CH , Punt CJ , et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17(1):127. Amin M , Edge S , Greene F , Byrd D , Brookland R , Washington M . AJCC Cancer Staging Manual. 8th ed. Berlin: Springer; 2017. Eisenhauer EA , Therasse P , Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. Moons KGM , Wolff RF , Riley RD , et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1-W33. Collins GS , Reitsma JB , Altman DG , Moons KGM . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. Choi SH , Park SW , Seong J . A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol. 2018;129(2):340-346. Vernerey D , Huguet F , Vienot A , et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Br J Cancer. 2016;115(3):281-289. Higuera O , Ghanem I , Nasimi R , Prieto I , Koren L , Feliu J . Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016;22(2):764-775. Castel-Kremer E , De Talhouet S , Charlois A-L , et al. An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. J Geriatr Oncol. 2018;9(4):373-381. Chen H-L , Zhou M-Q , Tian W , Meng K-X , He H-F . Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLOS One. 2016;11(10):e0165409. van Eeghen EE , Bakker SD , van Bochove A , Loffeld RJLF . Impact of age and comorbidity on survival in colorectal cancer. J Gastrointest Oncol. 2015;6(6):605-612. https://doi.org/10.3978/j.issn.2078-6891.2015.070. Vainshtein JM , Schipper M , Zalupski MM , et al. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escala. Int J Radiat Oncol Biol Phys. 2013;86(1):96-101. Peixoto RD , Speers C , McGahan CE , Renouf DJ , Schaeffer DF , Kennecke HF . Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4(8):1171-1177. Hohla F , Hopfinger G , Romeder F , et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-326. Cai S , Hong TS , Goldberg SI , et al. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013;119(23):4196-4204. Dohopolski MJ , Glaser SM , Vargo JA , Balasubramani GK , Beriwal S . Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival. J Gastrointest Oncol. 2017;8(5):766-777. Park HM , Park S-J , Han S-S , Kim SH . Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer. BMC Cancer. 2019;19(1):1090. Nakai Y , Isayama H , Sasaki T , et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78(3):252-259. Isaji S , Mizuno S , Windsor JA , et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11. van Veldhuisen E , Vogel JA , Klompmaker S , et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB. 2018;20(7):605-611. Aoki S , Motoi F , Murakami Y , et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019;19(1):252. Seufferlein T , Hammel P , Delpero JR , et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev. 2019;77:1-10. Katz MH , Fleming JB , Bhosale P , et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-5756. Verbeke C , Lohr M , Karlsson JS , Del , Chiaro M . Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer Treat Rev. 2015;41(1):17-26. Bednar F , Zenati MS , Steve J , et al. Analysis of predictors of resection and survival in locally advanced stage III pancreatic cancer: does the nature of chemotherapy regimen influence outcomes? Ann Surg Oncol. 2017;24(5):1406-1413. Klompmaker S , Peters NA , van Hilst J , et al. Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR): an International Multicenter Analysis. Ann Surg Oncol. 2019;26(3):772-781. Hosokawa Y , Nagakawa Y , Sahara Y , et al. Surgical outcomes of pancreaticoduodenectomy for pancreatic cancer with proximal dorsal jejunal vein involvement. J Gastrointest Surg. 2018;22(7):1179-1185. Springfeld C , Jäger D , Büchler MW , et al. Chemotherapy for pancreatic cancer. Presse Med. 2019;48(3 Pt 2):e159-e174. Reni M , Zanon S , Balzano G , et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(11):2786-2792. |
| فهرسة مساهمة: | Keywords: FOLFIRINOX; chemotherapy; locally advanced pancreatic cancer; resection; survival |
| المشرفين على المادة: | 0 (folfirinox) 04ZR38536J (Oxaliplatin) 7673326042 (Irinotecan) Q573I9DVLP (Leucovorin) U3P01618RT (Fluorouracil) |
| تواريخ الأحداث: | Date Created: 20210611 Date Completed: 20210819 Latest Revision: 20210819 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1002/jso.26567 |
| PMID: | 34115379 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9098 |
|---|---|
| DOI: | 10.1002/jso.26567 |